Trade

with

Novogen Ltd
(NASDAQ: NVGN)
AdChoices
2.77
+0.01
+0.36%
After Hours :
2.85
+0.08
+2.89%

Open

2.81

Previous Close

2.76

Volume (Avg)

8.62k (11.24k)

Day's Range

2.73-2.81

52Wk Range

2.68-6.84

Market Cap.

18.74M

Dividend Rate ( Yield )

-

Beta

0.89

Shares Outstanding

6.74M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.52M

    • Net Income

    • -904.27k

    • Market Cap.

    • 18.74M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -398.72

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.89

    • Forward P/E

    • -

    • Price/Sales

    • 2.35

    • Price/Book Value

    • 4.44

    • Price/Cash flow

    • -0.80

      • EBITDA

      • -912.17k

      • Return on Capital %

      • -70.06

      • Return on Equity %

      • -118.85

      • Return on Assets %

      • -70.06

      • Book Value/Share

      • 0.55

      • Shares Outstanding

      • 6.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -15.20

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -33.47

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 69.92

            • Pre-Tax Margin

            • -399.97

            • 21.84

            • Net Profit Margin

            • -398.72

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 91.00

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -270.30

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -124.30

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.32

              • Current Ratio

              • 1.60

              • 1.92

              • Quick Ratio

              • 1.60

              • 1.31

              • Interest Coverage

              • -5.86

              • 17.64

              • Leverage Ratio

              • 1.84

              • 2.03

              • Book Value/Share

              • 0.62

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.59

                • 21.88

                • P/E Ratio 5-Year High

                • -2.23

                • 193.96

                • P/E Ratio 5-Year Low

                • -0.10

                • 87.26

                • Price/Sales Ratio

                • 2.35

                • 3.70

                • Price/Book Value

                • 4.44

                • 3.69

                • Price/Cash Flow Ratio

                • -0.80

                • 13.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -118.85

                    (-43.60)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -70.06

                    (-26.50)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • -52.71

                    (-42.70)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • -

                  • 2.46

                  • Asset Turnover

                  • 0.18

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -1.21M
                  Operating Margin
                  -79.54
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -0.80
                  Ownership

                  Institutional Ownership

                  0.22%

                  Top 10 Institutions

                  0.21%

                  Mutual Fund Ownership

                  -

                  Float

                  -

                  5% / Insider Ownership

                  0.29%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Columbia Management Company

                  •  

                    3,000

                  • 0.00%

                  • 0.04

                  • Morgan Stanley Smith Barney LLC

                  •  

                    2,300

                  • -45.83%

                  • 0.03

                  • Merrill Lynch & Co Inc

                  •  

                    1,046

                  • 0.00%

                  • 0.02

                  • UBS Securities LLC

                  •  

                    927

                  • +32.62%

                  • 0.01

                  • UBS Financial Services Inc.

                  •  

                    500

                  • 0.00%

                  • 0.01

                  • Creative Planning, Inc.

                  •  

                    200

                  • 0.00%

                  • 0.00

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    78

                  • +160.00%

                  • 0.00

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  Novogen Ltd was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company’s competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.

                  Key People

                  Daniel P. Gold,PhD

                  CEO, Subsidiary/President, Subsidiary

                  Dr. Graham E. Kelly

                  CEO/Chairman of the Board/Director

                  Mr. Thomas Zech

                  CFO, Subsidiary

                  Mr. Mark G. Hinze

                  CFO, Subsidiary

                  Mr. Steven Coffey

                  CFO/Director

                  • Novogen Ltd

                  • 16-20 Edgeworth David Avenue

                  • Sydney, NSW 2077

                  • AUS.Map

                  • Phone: +61 294760344

                  • Fax: +61 294760388

                  • novogen.com

                  Incorporated

                  1994

                  Employees

                  5

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: